BUZZ-Drugmakers extend declines after Trump picks RFK Jr to lead top US health agency

Reuters11-15 23:13

(Updates)

** Shares of vaccine makers extend declines after President-elect Donald Trump selected Robert F. Kennedy Jr to lead the Department of Health and Human Services, the United States' top health agency

** U.S.-listed shares of BioNTech down ~5% to $98.41, Moderna falls 5.20% to $37.50, Novavax

down ~3% at $7, while Pfizer down 4.05% at $24.97

** Kennedy has frequently talked about tackling what he calls the "chronic disease epidemic" and is known to have spread misinformation on vaccines

** Shares in healthcare companies also drop in Europe

** Shares of U.S. drugmakers Eli Lilly down 2.7%, Merck down 3.34%, Amgen down 3.6%, Bristol Myers down 1.7%

** It is difficult to evaluate the exact impact this appointment could have on the industry until there is more information on specific policy proposals and priorities of the incoming administration on healthcare and the drug industry - Brokerage J.P.Morgan

** The broader SPDR S&P Biotech ETF down 3% in early U.S. trading

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment